First and only
no-mix prefilled
syringe
Streamlines workflow by
eliminating mixing time.1
Only 6-month
leuprolide WITH a
unique J-code (J1952)
Directly ties to CAMCEVI-specific
reimbursement.
Only 6-month
leuprolide with
a $0 co-pay*
AccordCares® helps your patients
start and stay on therapy.
*For eligible commercially insured patients.
CHOOSE CAMCEVI, THE EASY-TO-USE LEUPROLIDE
The leuprolide performance
you know and trust—simplified
For more than 30 years, leuprolides have been the
foundation of advanced prostate cancer treatment2
- CAMCEVI provides well-established safety and efficacy—but is the first and only leuprolide in a no-mix, prefilled, ready-to-inject syringe1
- Treatment with CAMCEVI can save valuable staff time by making preparation easy1
- CAMCEVI has a unique J-code and is the only 6-month leuprolide with a $0 co-pay
- CAMCEVI simplifies clinic workflow and supports patients, all while delivering dependable leuprolide testosterone suppression without breakthroughs1
Pasquale, CAMCEVI patient.
PATIENTS HAVE BEEN
TREATED WITH CAMCEVI3
1 in 3
TREATMENT-NAIVE
PATIENTS3
is prescribed a 6-month leuprolide, whereas only 17% receive a daily pill
>10000
TREATMENT-NAIVE
PATIENTS3
have received CAMCEVI
~6000
PATIENTS HAVE SWITCHED TO CAMCEVI3
from other injectable and oral products across 1-, 3-, 4-, and 6-month dosing schedules
Connect
with us live
Do not use CAMCEVI® in patients with hypersensitivity to GnRH, GnRH agonist analogs, or any of the components of CAMCEVI as anaphylactic reactions to these drugs have been reported in the medical literature.
CAMCEVI, like other GnRH agonists, causes a transient increase in serum levels of testosterone during the first week of treatment which can cause transient worsening of symptoms. As with other GnRH agonists, cases of ureteral obstruction and spinal cord compression have been observed, which may contribute to paralysis with or without fatal complications.
Patients with metastatic vertebral lesions and/or with urinary tract obstruction should be closely observed during the first few weeks of therapy.
Hyperglycemia and an increased risk of developing diabetes have been reported in men receiving GnRH agonists. Blood glucose levels should be monitored and managed according to current clinical practice.
Increased risk of myocardial infarction, sudden cardiac death, and stroke has been reported in association with the use of GnRH agonists. The risk appears low based on the reported odds ratios, and should be evaluated carefully along with cardiovascular risk factors when determining a treatment for patients with prostate cancer. Patients should be monitored for cardiovascular disease and be managed according to current clinical practice.
Androgen deprivation therapy may prolong the QT/QTc interval. Consider periodic monitoring of electrocardiograms and electrolytes.
Convulsions have been reported in patients receiving GnRH agonists, like CAMCEVI. Patients experiencing convulsions should be managed according to the current clinical practice.
CAMCEVI can cause severe cutaneous adverse reactions (SCARs), including Stevens-Johnson syndrome/toxic epidermal necrolysis, drug reaction with eosinophilia and systemic symptoms (DRESS), and acute generalized exanthematous pustulosis (AGEP). Interrupt CAMCEVI if signs or symptoms of SCARs develop. Permanently discontinue if SCARs are confirmed.
Monitor serum levels of testosterone following injection of CAMCEVI.
Based on findings in animal studies and mechanism of action, CAMCEVI may cause fetal harm when administered to pregnant women.
The most common (≥10%) adverse reactions during a median follow-up of 336 days were hot flush, hypertension, injection site reactions, upper respiratory tract infections, musculoskeletal pain, fatigue, and pain in extremity.
INDICATION
CAMCEVI is indicated for the treatment of adult patients with advanced prostate cancer.
Click here for full Prescribing Information.
